These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11267204)

  • 1. The impact of antilymphocyte therapy on sensitized patients in renal transplantation.
    Santi S; Fop F; Segoloni G; Piccoli G
    Transplant Proc; 2001; 33(1-2):1090. PubMed ID: 11267204
    [No Abstract]   [Full Text] [Related]  

  • 2. Antilymphocyte antibodies, renal transplantation, and meta-analysis.
    Levey AS; Schmid CH; Lau J
    Ann Intern Med; 1998 May; 128(10):863-5. PubMed ID: 9599200
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody therapy in steroid-resistant rejection.
    Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of antithymocyte globulin treatment of steroid-resistant acute rejection in kidney transplantation.
    Bertoni E; Maccario M; Biagini M; Montagnino G; Piperno R; Tarantino A; Salvadori M
    Transplant Proc; 2001; 33(7-8):3337. PubMed ID: 11750426
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
    Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
    Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of ATG prophylaxis in sensitized and non-sensitized kidney graft recipients.
    Kaden J; May G; Schönemann C; Müller P; Groth J; Seeger W; Seibt F; Henkert M; Lippert J
    Transpl Int; 1992; 5 Suppl 1():S75-8. PubMed ID: 14621739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract]   [Full Text] [Related]  

  • 8. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
    Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
    Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of antithymocyte globulin induction treatment on renal transplant outcome.
    Sanchez-Fructuoso AI; Naranjo P; Torrente J; Fernández-Pérez C; Avilés B; Prats D; Barrientos A
    Transplant Proc; 1998 Aug; 30(5):1790-2. PubMed ID: 9723284
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation between Banff classification and reversal of acute renal rejection.
    Kokado Y; Kyo M; Takahara S; Ichimaru N; Wang JD; Toki K; Miki T; Okuyama A
    Transplant Proc; 1998 Nov; 30(7):3064-6. PubMed ID: 9838350
    [No Abstract]   [Full Text] [Related]  

  • 12. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.
    Takahashi K; Ochiai T; Uchida K; Yasumura T; Ishibashi M; Suzuki S; Otsubo O; Isono K; Takagi H; Oka T
    Transplant Proc; 1995 Feb; 27(1):1421-4. PubMed ID: 7878933
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of OKT3 treatment for steroid resistant rejection of renal allografts: the long-term outcome at a single center.
    Inui M; Tanabe K; Ishikawa N; Tokumoto T; Harano M; Otsubo S; Suzuki K; Goya N; Yagisawa T; Nakazawa H; Fuchinoue S; Toma H
    Transplant Proc; 1999 Nov; 31(7):2870-1. PubMed ID: 10578320
    [No Abstract]   [Full Text] [Related]  

  • 14. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus therapy for ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Sonda K; Nakagawa Y; Katagiri A; Tomita Y; Tanigawa T; Takeda M
    Transplant Proc; 1998 Jun; 30(4):1219-20. PubMed ID: 9636495
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
    Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
    Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
    [No Abstract]   [Full Text] [Related]  

  • 17. Kidney transplantation in pediatric population.
    Mota C; Henriques C; Sarmento M; Pereira E; Xavier E; Pereira M
    Transplant Proc; 1994 Oct; 26(5):2768-70. PubMed ID: 7940872
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney transplantation from donors without a heartbeat.
    Luan FL
    N Engl J Med; 2002 Nov; 347(22):1799-801; author reply 1799-801. PubMed ID: 12462226
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.